Siglec15 in Blood System Diseases
Author Information
Author(s): Fan Yujia, Sun Liangliang, He Juan, Chen Yuetong, Ma Hongli, Ding Haitao
Primary Institution: Baotou Medical College of Inner Mongolia University of Science and Technology
Hypothesis
The study reviews the role of Siglec-15 in various blood system diseases and its potential as a therapeutic target.
Conclusion
Siglec-15 is implicated in immune evasion in cancers and may serve as a promising target for immunotherapy in hematological diseases.
Supporting Evidence
- Siglec-15 is up-regulated in various cancer types, indicating its role in immune evasion.
- Targeting Siglec-15 may enhance the effectiveness of immunotherapy in hematological malignancies.
- Siglec-15 can modulate immune responses to microbial infections.
Takeaway
Siglec-15 is a protein that helps cancer cells hide from the immune system, and scientists think it could be a good target for new cancer treatments.
Methodology
The study is a review of existing literature on Siglec-15's biological attributes, expression patterns, and mechanisms in various diseases.
Limitations
The review is based on existing literature and may not include all recent findings or clinical data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website